Company / SG&A Expense
Envista Holdings SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.2B
FY2025
5-year range
$1.0B / $1.2B
FY2021-FY2025
Trend
-0.1%
vs FY2024
Sector context
#41 of 152
Health Care
What the data says
At $1.2B, Envista Holdings's sg&a expense ranks #112 of 152 in the Health Care sector. SG&A Expense has fluctuated over the past 9 years, ranging from $925M in FY2020 to $1.2B in FY2024.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +4.6%.
Increased from $1.1B to $1.2B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +3.1%
- 5-Year CAGR
- +4.6%
- 10-Year CAGR
- -
Sector benchmark
#112 of 152 in Health CareTop 73% of 152This company $1.2B Sector average $182.7B
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.6%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.1% year-over-year.
- Ranks #41 out of 152 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | -0.1% |
| FY2024 | $1.2B | +9.6% |
| FY2023 | $1.1B | +0.1% |
| FY2022 | $1.1B | +3.5% |
| FY2021 | $1.0B | +10.3% |
| FY2020 | $924.6M | -5.7% |
| FY2019 | $980.4M | -13.3% |
| FY2018 | $1.1B | +6.5% |
| FY2017 | $1.1B | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026